Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
Total Valuation
Orchestra BioMed Holdings has a market cap or net worth of $161.87M. The enterprise value is $85.32M.
Market Cap$161.87M
Enterprise Value$85.32M
Share Statistics
Orchestra BioMed Holdings has 53,955,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,955,086
Owned by Insiders30.53%
Owned by Institutions25.32%
Financial Efficiency
Orchestra BioMed Holdings’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is -105.30%.
Return on Equity (ROE)-1.85
Return on Assets (ROA)-0.80
Return on Invested Capital (ROIC)-105.30%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee37.69K
Profits Per Employee-871.77K
Employee Count70
Asset Turnover0.03
Inventory Turnover1.18
Valuation Ratios
The current PE Ratio of Orchestra BioMed Holdings is ―. Orchestra BioMed Holdings’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value4.47
Price to FCF―
Price to Operating Cash Flow-1.72
PEG Ratio―
Income Statement
In the last 12 months, Orchestra BioMed Holdings had revenue of 2.64M and earned -61.02M in profits. Earnings per share was -1.66.
Revenue2.64M
Gross Profit2.43M
Operating Income-64.30M
Pretax Income-61.02M
Net Income-61.02M
EBITDA-64.30M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was -59.38M and capital expenditures -320.00K, giving a free cash flow of -59.70M billion.
Operating Cash Flow-59.38M
Free Cash Flow-59.70M
Free Cash Flow per Share-1.11
Dividends & Yields
Orchestra BioMed Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.17
52-Week Price Change-59.43%
50-Day Moving Average2.88
200-Day Moving Average3.95
Relative Strength Index (RSI)48.64
Average Volume (3m)369.64K
Important Dates
Orchestra BioMed Holdings upcoming earnings date is Nov 18, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Orchestra BioMed Holdings as a current ratio of 4.27, with Debt / Equity ratio of 667.80%
Current Ratio4.27
Quick Ratio4.26
Debt to Market Cap0.10
Net Debt to EBITDA0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Orchestra BioMed Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Orchestra BioMed Holdings EV to EBITDA ratio is -2.20, with an EV/FCF ratio of -2.78.
EV to Sales53.66
EV to EBITDA-2.20
EV to Free Cash Flow-2.78
EV to Operating Cash Flow-2.80
Balance Sheet
Orchestra BioMed Holdings has $33.92M in cash and marketable securities with $1.97M in debt, giving a net cash position of -$31.95M billion.
Cash & Marketable Securities$33.92M
Total Debt$1.97M
Net Cash-$31.95M
Net Cash Per Share-$0.59
Tangible Book Value Per Share$0.90
Margins
Gross margin is 92.66%, with operating margin of -2437.49%, and net profit margin of -2313.27%.
Gross Margin92.66%
Operating Margin-2437.49%
Pretax Margin-2313.27%
Net Profit Margin-2313.27%
EBITDA Margin-2437.49%
EBIT Margin-2437.49%
Analyst Forecast
The average price target for Orchestra BioMed Holdings is $3.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$3.00
Price Target Upside5.63% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast41.61%
EPS Growth Forecast-17.39%